硕肯生物硕肯生物Soken.bio
查看试用产品 →开放浏览 · 登录后申请
人 CDC42BPA 抗体对
试剂盒

人 CDC42BPA 抗体对

01AB02136

CDC42 binding protein kinase alpha (CDC42BPA) is a DMPK-related serine/threonine kinase that serves as a downstream effector of the Rho GTPase CDC42. It regulates actomyosin contractility, lamellipodial F-actin dynamics, and cell migration by phosphorylating key targets such as MYL9, LIMK1/2, and CFL1. The protein contains a CRIB domain for CDC42 binding and a kinase domain that mediates Rho GTPase signaling. Beyond cytoskeletal reorganization, CDC42BPA participates in TFRC-mediated iron uptake and the extrusion of apoptotic cells from epithelia. Clinically, CDC42BPA is linked to myotonic dystrophy due to its functional homology with DMPK. Additionally, altered CDC42BPA activity is implicated in the invasive and metastatic potential of various cancers, where it drives the cellular motility required for tumor progression.

Human
规格起售价
登录后可查看

技术参数

靶点基因名
CDC42BPA
基因别名
KIAA0451
蛋白别名
CDC42 binding protein kinase alpha; CDC42BPA
UniProt
Q5VT25
物种
Human

产品详情

靶点名称
CDC42BPA
蛋白名称
CDC42 binding protein kinase alpha
蛋白别名
Serine/threonine-protein kinase MRCK alpha; CDC42-binding protein kinase alpha; DMPK-like alpha; Myotonic dystrophy kinase-related CDC42-binding kinase alpha; MRCK alpha; Myotonic dystrophy protein kinase-like alpha
靶点基因名
CDC42BPA
基因别名
KIAA0451
UniProt
Q5VT25
来源物种
Homo sapiens (Human)
物种反应性
Human

背景介绍

CDC42 binding protein kinase alpha (CDC42BPA) is a DMPK-related serine/threonine kinase that serves as a downstream effector of the Rho GTPase CDC42. It regulates actomyosin contractility, lamellipodial F-actin dynamics, and cell migration by phosphorylating key targets such as MYL9, LIMK1/2, and CFL1. The protein contains a CRIB domain for CDC42 binding and a kinase domain that mediates Rho GTPase signaling. Beyond cytoskeletal reorganization, CDC42BPA participates in TFRC-mediated iron uptake and the extrusion of apoptotic cells from epithelia. Clinically, CDC42BPA is linked to myotonic dystrophy due to its functional homology with DMPK. Additionally, altered CDC42BPA activity is implicated in the invasive and metastatic potential of various cancers, where it drives the cellular motility required for tumor progression.